Navigation Links
Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
Date:5/21/2008

ing provided under a collaborative agreement between Romark and F. Hoffmann-La Roche Ltd.

Romark recently announced enrollment for its STEALTH C-3 clinical trial, a Phase II randomized, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of nitazoxanide in combination with peginterferon alfa-2a and ribavirin in treatment nave patients with chronic hepatitis C infected with genotype 1. Enrollment for the STEALTH C-3 study began in April 2008 and the trial will enroll 60 patients at 15 centers in the U.S.

The primary objective of STEALTH C-3 is to evaluate sustained virologic response (SVR) with a treatment regimen of 4 weeks of nitazoxanide lead-in therapy followed by 48 weeks of standard of care plus nitazoxanide versus 4 weeks of placebo lead-in followed by 48 weeks of standard of care and placebo.

About Nitazoxanide

Nitazoxanide belongs to a new class of small molecule kinase activators called the thiazolides. Like interferons, thiazolides modulate cell signaling pathways involved in the host cell's innate defense against viruses. Thiazolides can be administered orally and are not associated with side effects commonly associated with use of interferon. Nitazoxanide was discovered by Jean-Francois Rossignol, M.D., Ph.D., Chairman and Chief Science Officer of Romark, and was initially developed by Romark and approved for marketing in the United States as a treatment for cryptosporidiosis. Recent laboratory studies have shown that nitazoxanide does not induce resistance mediated by mutations in the viral genome.

About Hepatitis C

Hepatitis C is a blood-borne infectious disease that is caused by the hepatitis C virus (HCV). It is the most common cause of chronic hepatitis in the U.S. and may eventually lead to cirrhosis, liver cancer and liver failure. The disease is transmitted by contact with HCV-infected blood. A large majority of those infected do not show symptoms, but fatigue, abdominal pa
'/>"/>

SOURCE Romark Laboratories, L.C.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008
2. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
3. Romark Laboratories Raises $18 Million in Institutional Financing
4. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
5. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
6. Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers
7. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
8. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
9. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
10. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
11. Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Vernak, RPh, of Vernak Farms Pharmacy in ... George Roentsch Scholarship by the Professional Compounding Centers of ... Houston during PCCA,s International Seminar, held October ... independent pharmacist and PCCA member who embodies the innovative ... well-known pharmacist in the compounding community. ...
(Date:10/22/2014)... , Oct. 22, 2014 AVACEN Medical ... device received 510 (k) OTC clearance by the U.S. ... 100 to be marketed over the Internet for: ... muscle spasms; and minor strains and sprains . ... The AVACEN 100 (MSRP $2495) is a sophisticated medical ...
(Date:10/22/2014)... , October 22, 2014 ... ), a clinical-stage pharmaceutical company focused on the ... positive top-line clinical results from its Phase IIa ... insulin capsules, to treat type 1 diabetes. The trial ... under a U.S. Food and Drug ...
Breaking Medicine Technology:PCCA Awards Charlene Vernak, RPh, the George Roentsch Scholarship 2AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... may lead to increased blood pressure, according to a new ... in blood pressure for young adult women or for teenagers, ... drank lightly or moderately, their risk of high blood pressure ... parallels studies in older adult men and women," said lead ...
(Date:10/22/2014)... News) -- Measures taken by Firestone officials at the ... have limited the spread of the disease there and ... Natural Rubber Co. provides health services to about 80,000 ... populated communities. Between Aug. 1 and Sept. 23, ... those 80,000 people. That incidence rate of 0.09 percent ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... cameraman who was diagnosed with Ebola while working for NBC ... and can leave the special isolation unit at Nebraska Medical Center ... weeks, the hospital said Tuesday. A blood test confirmed by ... Mukpo, 33, can head home to Providence, R.I., NBC News ...
(Date:10/20/2014)... With a mere 19 days to November ... brief fundraising stop at the  Law Offices of ... a debate last night with his opponent Gov. Rick ... first seven minutes because Crist had an electric fan ... in one word: "weird." , Before touching on his ...
(Date:10/20/2014)... The Advocator Group, LLC is ... Foundation for Suicide Prevention’s (AFSP) Out of the Darkness ... organization that hosts hundreds of community walks throughout the ... used to help understand and prevent suicide through not ... well. , The Advocator Group shares this passion ...
Breaking Medicine News(10 mins):Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3
... care at community health clinics especially women ... cardiologist than those who receive primary care at hospitals, ... the American Heart Association . , Researchers from the ... Medical School reviewed the electronic medical records of 9,761 ...
... April 27 Robert J. Gould, a behavioral ... nation,s most successful social marketing campaigns, has been ... by Partnership,s board of directors was announced today ... board."Rob,s unique combination of behavioral science expertise, proven ...
... a worrisome rise in childhood obesity, Florida school districts ... but there is little research available to determine if ... a $2.2 million grant from the National Institutes of ... a Florida State University College of Medicine researcher will ...
... today that, working with the UN Refugee Agency (UNHCR), it will send ... African countries. , ... Washington, D.C. (Vocus) April 27, 2009 -- The ... Refugee Agency (UNHCR), it will send over 346,000 life-saving bed nets to ...
... April 27 50,000 hand addressed letters were sent to ... Notre Dame officials, urging ND Grads to fight ... sent 50,000 letters to Alumni from ,88 and back. (Older ... post cards are designed to be sent to Vatican and ...
... Company (Nasdaq: STAA ) today announced that it will release financial ... May 5, 2009 after ... host a conference call and webcast on Tuesday, ... 1:30 p.m. Pacific to discuss the Company,s first quarter results ...
Cached Medicine News:Health News:Patients at community health clinics less likely to be referred to cardiologist 2Health News:Patients at community health clinics less likely to be referred to cardiologist 3Health News:Robert J. Gould Named President at Partnership for Prevention 2Health News:FSU researcher wins $2.2 million grant to study childhood obesity 2Health News:FSU researcher wins $2.2 million grant to study childhood obesity 3Health News:UN Foundation to Help Protect More than a Million Refugees from Malaria in Africa 2Health News:50,000 Letters Sent to Notre Dame Alumni Re: Obama; In Letter, Bishop Gracida Urged Former U.S. Ambassador to the Vatican Mary Ann Glendon to Refuse Award 2Health News:STAAR Surgical Announces First Quarter 2009 Earnings Release Date and Conference Call 2
Advanced operating microscope with zoom and variable focus up to 500 mm....
PS Medical lumboperitoneal catheter systems are designed to divert CSF from the lumbar subarachnoid space to the peritoneal cavity, using simplified surgical techniques....
Micro Dissecting Curette, 5 1/2", Round....
10 overall length 4.5 from bend 250 mm. 90...
Medicine Products: